Background: The European Best Practice Guidelines on anticoagulation in chronic haemodialysis recommend the use of low-molecular-weight heparins (LMWH) over unfractionated heparin (UFH), based on previous small-scale studies and a meta-analysis which demonstrated equal efficacy of anticoagulation without an increase in hemorrhagic events. Method: We performed a prospective single-centre study where all stable patients on chronic in-hospital haemodialysis were converted from UFH to Tinzaparin™. Patients were monitored for 2 months before and 2 months after the switch. Access failures due to thrombosis, clotted circuits and hemorrhagic events were recorded. Results: 1,489 and 1,823 dialysis sessions took place on UFH and LMWH, respectively, in 108 patients (65 male). The total number of clotted circuits tended to decrease after the switch to LMWH (34 vs. 13) but was not statistically significant. There were four minor non-access-related episodes of haemorrhage while on treatment with UFH and none with Tinzaparin, and the length of bleeding time post needle removal was shorter with Tinzaparin than UFH. The cost-analysis demonstrated parity of Tinzaparin with UFH; using a median of 10,000 U of UFH versus 2,500 U of LMWH, each therapy cost GBP 10,783 (EUR 15,942; USD 20,446) per annum. Conclusion: Our findings suggest comparable safety and efficacy of Tinzaparin, parity of cost in comparison with UFH.

Keywords:
Low-molecular-weight heparin, Anticoagulation, Haemodialysis
1.
Hetzel GR, Sucker C: The heparins: all a nephrologist should know. Nephrol Dial Transplant 2005;20:2036–2042.
2.
Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S, Houghton JB, et al: Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 2004;43:531–537.
3.
Antonelli D, Fares L 2nd, Anene C: Enoxaparin associated with huge abdominal wall hematomas: a report of two cases. Am Surg 2000;66:797–800.
4.
Kruzel-Davila E, Frajewicki V, Kushnir D, Eyal A, Kohan R: Retroperitoneal hematoma in a haemodialysis patient receiving low molecular weight heparin. Israel Med Assoc J 2005;7:611–612.
5.
Ueda A, Nagase S, Morito N, Yotsumoto M, Ohba S, Hasegawa Y, Narita M, Koyama A: Anaphylactoid reaction induced by low-molecular-weight heparin in a haemodialysis patient. Nephron 2001;87:93–94.
6.
Basic-Jukic N, Kes P: Severe anaphylactic reaction in a haemodialysis patient after administration of reviparin. Nephrol Dial Transplant 2004:19:1021–1022.
7.
Lim W, Cook DJ, Crowther MA: Safety and efficacy of low molecular weight heparins for hemodialysis patients with end-stage renal failure: a meta-analysis of randomized controlled trials. J Am Soc Nephrol 2004;15:3192–3206.
8.
Lim W, Dentali F, Eikelboom JW, Crowther MA: Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673–684.
9.
Lord H, Jean N, Dumont M, Kassis J, Leblanc M: Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 2002;22:58–66.
10.
Saltissi D, Moragan C, Westhuyzen J, Healy H: Comparison of low molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999;14:2698–2703.
11.
Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. JASN 2002;13(suppl 1):S37–S40.
12.
Ploth DW, Shepp PH, Counts C, Hutchison F: Prospective analysis of global costs for maintenance of patients with ESRD. Am J Kidney Dis 2003;42:12–21.
13.
NKF K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients: Section III. State of the Science: Novel and Controversial Topics in Cardiovascular Diseases. Intradialytic Hypotension. New York, National Kidney Foundation, 2000.
14.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140. Erratum in: Am J Infect Control 1988;16:177.
15.
Pearson ML: Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections: an overview. The Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996;24:262–277.
16.
European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association: Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporeal system. Nephrol Dial Transplant 2002;17(suppl 7):63–71.
17.
Laposata M, Green D, Van Cott EM, et al: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998;122:799–807.
18.
Bristol-Myers Squibb Pharma Co: Innohep (tinzaparin sodium injection) US Package Insert. Wilmington, Bristol-Myers Squibb Pharma, 2001.
19.
Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barners JF: Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771–775.
20.
Busby LT, Weyman A, Rodgers GM: Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001;67:54–56.
21.
Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM: Safety and efficacy of unfrationated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003;146:33–41.
22.
Klingel R, Schwarting A, Lotz J, Eckert M, Hohman V, Hafner G: Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic haemodialysis. Results of an open-label post-certification study. Kidney Blood Press Res 2004;27:211–217.
23.
Egfjord M, Rosenlund L, Hedegaard B, Buchardt HL, Stengel C, Gardar P, Anderson L, Anderson L: Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis. Artif Organs 1998;22:633–637.
24.
Matthiasson SE, Lindblad B, Stjernquist U, Bergqvist D: The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 1995;25:203–211.
25.
Greaves M; Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis: Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;87:163–164.
26.
Carr ME, Martin EJ, Kuhn JG, Spiess BD: Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemost 2003;1:1977–1983.
27.
Butenas S, van’t Veer C, Mann KG: ‘Normal’ thrombin generation. Blood 1999;94:2169–2178.
28.
Carr ME Jr: Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 2003;38:55–78.
29.
Brophy DF, Martin EJ, Gehr TW, Carr ME Jr: Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004;44:270–277.
30.
Crowther MA, Berry LR, Monagle PT, Chan AK: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178–186.
31.
Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J: Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1988;60:407–410.
32.
Beijering RJR: ISBN 90–9011750–4.
33.
Schrader J, Stibbe W, Armstrong VW, et al: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890–896.
34.
Bambauer R, Rücker S, Weber U, Köhler M: Comparison of low-molecular weight to standard heparin in hemodialysis. ASAIO Trans 1990;36:M646–M649.
35.
Ryan KE, Lane DA, Flynn A, et al: Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991;66:277–282.
36.
Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, et al: Intravenous and subcutaneous weight-bases dosing of the low molecular weight heparin Tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002;40:531–538.
37.
Lai KN, Wang AY, Ho K, Szeto CC, Li M, Wong LK, et al: Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis 1996;28:721–726.
38.
Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Fauchald P, Brosstad F: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999;14:1943–1947.
39.
Simpson HK, Baird J, Allison M, et al: Long-term use of the low-molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996;26:90–97.
40.
Polkinghorne KR, McMahon LP, Becker GJ: Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Disease 2002;40:990–995.
41.
Deuber HJ, Schulz W: Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991;40:496–500.
42.
Elisaf MS, Germanos NP, Bairaktari HT, Pappas MB, Koulouridis EI, Siamopoulos KC: Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 1997;17:153–157.
43.
Pettilä V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E: Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 1999;96:275–282.
44.
Oster JR, Singer I, Fishman LM: Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995;98:575–586.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.